Noxopharm Ltd. · ASX:NOX
Noxopharm — Non-Deal Roadshow (January 2020)
26 slides from Noxopharm's roadshow presentation, Jan 29, 2020
Slide 1: Noxopharm Non-Deal Roadshow Presentation
For personal use only Date: 29th January 2020 Sydney, Australia Noxopharm Non-Deal Roadshow Presentation Sydney, 29th January 2020: Noxopharm (ASX: NOX) is pleased to provide shareholders and the market the attached Noxopharm corporate presentation “Non-Deal Roadshow Presentation”. This document is
Slide 2: Forward Looking Statements
For personal use only uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. Suite 3, Level 4, 828 Pacific Highway, Gor
Slide 3: Noxopharm Limited Veyonda Non-Deal Roadshow Presentation
January 2020 For personal use only Noxopharm Limited Veyonda® Non-Deal Roadshow Presentation DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX For pers
Slide 5: Non-Deal Roadshow Presentation
Non-Deal Roadshow Presentation For personal use only Dr Gisela Mautner 1 Medical Overview Mr Alex Hunter 2 Corporate Overview Veyonda® Noxopharm is seeking to bring Veyonda® to market as a first-in-class drug that combines with radiotherapy to provide a potent anti-cancer effect in prostate cancer ©
Slide 6: Medical Overview
Dr Gisela Mautner MD-PHD, MPH, MBA For personal use only Medical Overview Drug development process Prostate cancer Veyonda® Veyonda® DARRT LuPIN Veyonda® market potential Indicative clinical program timing © 2020 Noxopharm Ltd. All rights reserved.
Slide 7: Drug Development Process
Drug Development Process For personal use only Veyonda® © 2020 Noxopharm Ltd. All rights reserved.
Slide 8: Men who develop prostate cancer
For personal use only 1 in 5 men develop prostate cancer before they turn 85 © 2020 Noxopharm Ltd. All rights reserved.
Slide 9: Prostate Cancer and Treatment Options
Prostate Cancer and Treatment Options only Course of Disease and Treatment Journey for Stage I - IV Prostate Cancer use Surgery Chemical Androgen Palliative therapy Chemo- and/or local castration & receptor Rising PSA levels in blood therapy radiotherapy therapy inhibitors For personal Veyonda® DARR
Slide 10: Veyonda Acts in a Unique Space
Veyonda® Acts in a Unique Space For personal use only 1 drug RT & Veyonda® Life-extending treatment 1 drug 1 drug RT & Veyonda® 1 drug 1 drug 1 drug RT & Veyonda® 1 drug 1 drug 1 drug 1 drug RT & Veyonda® Irrespective of how many new drugs are coming to market, they will generally not affect Veyonda
Slide 11: Veyonda – Clinical Study DARRT-1
1 Veyonda® – Clinical Study DARRT-1 For personal use only Ø 26 men enrolled with late-stage prostate cancer Ø Metastatic castration-resistant prostate cancer (mCRPC) Ø Progressive disease Ø No remaining standard treatment options Ø Eligible for palliative RT for symptomatic relief Ø Treatment with l
Slide 12: DARRT-1: Safety and Tolerability
11 DARRT-1: Safety and Tolerability For personal use only Ø Primary end-point of acceptable safety and tolerability was met Ø Treatment well tolerated with no serious side-effects due to Veyonda® Ø No dose-limiting toxicities ü Veyonda® in combination with radiation therapy was reported to be safe a
Slide 13: DARRT-1: Efficacy – Tumour Response
11 DARRT-1: Efficacy – Tumour Response Ø In the 15* patients who were evaluable at 6 For personal use only months1 The Tumours stopped growing or reduced in size in 10 patients (1 patient achieved a partial response and 9 achieved stable disease at 6 months) Overall (RECIST1.1) N=10 N=5 N=15 Complet
Slide 14: DARRT-2 – In Planning
2 DARRT-2 – In Planning Ø Building on the experience and data of DAART-1 For personal use only Ø Phase 2 trial Ø Multinational Ø Min. 60 patients Ø Same patient population as in DARRT-1 Ø Radiation therapy plus repeated cycles of Veyonda® Ø Medical Advisory Boards established Ø Protocol synopsis bei
Slide 15: Additional Opportunity in Prostate Cancer
Additional Opportunity in Prostate Cancer For personal use only External Radiation Internal Radiation Ø Standard-of-Care Ø Experimental Ø Widely used Ø Billion-dollar Acquisition by Novartis DARRT LuPIN © 2020 Noxopharm Ltd. All rights reserved.
Slide 16: LuPIN – Comparative Results
LuPIN – Comparative Results For personal use only § Progression-free survival (PFS) is a measure of the time from the start of treatment until the disease progresses. ü Median PFS quadrupled through the addition of Veyonda® (8.4 months vs 2.0 months with 177Lu-PSMA alone) § Treatment duration ü The
Slide 17: Market Potential – Prostate Cancer
Market Potential – Prostate Cancer For personal use only CURRENT treatment FUTURE treatment opportunity Prostate Cancer Radiotherapy Radiotherapy & alone Veyonda® © 2020 Noxopharm Ltd. All rights reserved.
Slide 18: Market Opportunities – RT plus Veyonda
Market Opportunities – RT plus Veyonda® For personal use only Prostate Cancer Others (20%) Breast Cancer Palliative therapy Thyroid Cancer Lung Cancer Kidney Cancer © 2020 Noxopharm Ltd. All rights reserved.
Slide 19: Indicative Clinical Program Timing
Indicative Clinical Program Timing For personal use only MarQ2020 MarQ2021 DecQ2019 DecQ2020 DecQ2021 SepQ2020 SepQ2021 JunQ2020 JunQ2021 DARRT -1 complete, Indicative Clinical Program Timing final statistical results due March 2020 DARRT-1 Phase 1 clinical trial complete Dec Q 2019 Phase 1 statisti
Slide 20: Corporate Overview
Mr Alex Hunter MBA, BE, GradDipCorpSecFinLaw, GradDipAppFin For personal use only Corporate Overview Executive Summary Company Details Market Opportunity Veyonda® Nyrada Inc. Investment Highlights © 2020 Noxopharm Ltd. All rights reserved.
Slide 21: Executive Summary
Executive Summary For personal use only Ø Australian biotech company listed on Australian Securities Exchange (ASX:NOX) Ø Oncology focus Ø Proprietary drug Veyonda® well advanced in clinical development phase Ø First-in-class inhibitor of sphingosine-1-phosphate Ø Intended as adjunct to radiotherapy
Slide 22: Company Details
Company Details For personal use only Noxopharm Limited (Jan 2020) Board and Key Management Listed on Australian Securities Exchange (ASX:NOX) Aug 2016 Dr Graham Kelly. PhD Chairman & CEO Shares on issue 132m Ian Dixon. PhD, MBA Non-Executive Director Share Price A$0.23.5-A$0.29 Peter Marks. MBA, BE
Slide 23: Market Opportunity
2 Market Opportunity For personal use only Market Opportunity Noxopharm believes § Noxopharm believes Veyonda® has potential applications in most forms of solid cancer as both a radio-enhancer Veyonda® has potential and chemo-enhancer use in most forms of solid § Noxopharm has selected radio-enhance
Slide 24: Nyrada Inc.
2 Nyrada Inc. (ASX:NYR) For personal use only NYRADA § Nyrada is a pre-clinical stage, drug company specialising in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases Noxoph
Slide 25: Noxopharm Investment Highlights
Investment Highlights For personal use only Noxopharm Investment Highlights § Significant clinical milestones over next 12 months from DARRT and LuPIN trials § Potential standard of care: Noxopharm believes that its DARRT and LuPIN treatments have the potential to become standard of care for late-st
Slide 26: For further information please visit www.noxopharm.com
For personal use only For further information please visit www.noxopharm.com Veyonda® DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.